FREDERICK, Md., May 10, 2016 /PRNewswire/ — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices, announced that it remains in negotiations with the U.S. Food and Drug Administration (“FDA”) regarding its 510(k) premarket notification for the ActiPatch® Musculoskeletal Pain Therapy. Two weeks ago, it submitted detailed responses to the FDA’s questions related to the … Continue Reading
Author Archives
Adam Staelin
BioElectronics’ Drug-free ActiPatch® Pain Therapy Highlighted in UK’s Express Newspaper on Dangers of Excessive Drug Use
FREDERICK, Md., April 28, 2016 /PRNewswire/ — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its drug-free ActiPatch® product was noted in the United Kingdom’s Express Newspaper Health Section, http://www.express.co.uk/life-style/health/664330/arthritis-pain-pills-warning-sufferers-taking-too-many-drugs-fight-agony. The paper has a circulation of 400,000 that will increase the awareness of ActiPatch therapy for arthritis and chronic pain. The … Continue Reading
Bioelectronics Compay Update April 7, 2016
BioElectronics Wins “Best OTC Marketing Campaign on a Small Budget” The OTC Bulletin, the leading global trade publication for over-the-counter healthcare products, has chosen ActiPatch® Musculoskeletal Chronic Pain Relief Therapy as the winner for the “Best OTC Marketing Campaign on a Small Budget” award. A panel of six independent over-the-counter marketing experts evaluated the seven … Continue Reading